Assessing the treatment of solar urticaria. The dose-response as a quantifying approach.

Abstract

The weal and flare produced by monochromatic irradiation in solar urticaria may be treated as a classical dose-response. This has been used to investigate therapy with H1 and H2 antihistamines. The conventional H1 drug proved superior. But from the practical viewpoint, solar urticaria is difficult to suppress even with a relatively efficient H1 Antihistamine, chlorpheniramine; the mean protective factor in 5 patients was only 2, insufficient for satisfactory clinical management.

• Authors: P Michell, J L Hawk, A Shafrir, M F Corbett, I A Magnus
• Journal: Dermatologica (Dermatologica) Vol. 160 Issue 3 Pg. 198-207 ( 1980) ISSN: 0011-9075 [Print] Switzerland
• PMID: 6104610 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Histamine H1 Antagonists
• Histamine H2 Antagonists
• Placebos
• Chlorpheniramine
• Cimetidine

Topics

• Adult
• Chlorpheniramine (therapeutic use)
• Cimetidine (therapeutic use)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Histamine H1 Antagonists (therapeutic use)
• Histamine H2 Antagonists (therapeutic use)
• Humans
• Male
• Middle Aged
• Placebos
• Ultraviolet Rays (adverse effects)
• Urticaria (drug therapy)